UAE Announces 86% Efficacy of Sinopharm Vaccine for COVID-19: Plans Rollout




On Wednesday, the Health Ministry of the United Arab Emirates revealed that the coronavirus vaccine developed by Chinese company Sinopharm has proven to be 86% effective in protection against COVID 19. The ministry has announced that it has registered for the vaccine.

This decision comes after the promising results seen from the late-stage trials that the Chinese company has been conducting in the UAE and several countries.

“The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine,” the health ministry said.

31,000 volunteers across 125 nationalities of the country were involved in the trials conducted for this vaccine. Trial results have shown “no serious safety concerns,” the health ministry stated. While detailed data is yet to be made available to the general public, reports say that the Chinese company is still in the process of its late-stage clinical trials.

What UAE’s next move would be in the development of the vaccine could be a wait-and-watch scenario. The health ministry has not revealed its next steps yet and it is unclear whether it has plans to deploy the Sinopharm vaccine throughout the country. However, the ministry confirmed on Tuesday that 8,260 new cases COVID-19 have been reported in the country, which could push towards accelerated efforts.

According to a press release, Morocco also has plans to implement an immunization program and aims to get at least 80% of its adult population vaccinated with the Chinese vaccine.

UAE’s approval and registration of the vaccine follows the United Kingdom’s announcement its countrywide immunization program. A day before the UAE announcement, the U.S. Food and Drug Administration revealed that the coronavirus vaccine developed by Pfizer and BioNTech has shown “no specific safety concerns” that could preclude an approval for its emergency use. This announcement clears the path for a possible launch that is expected in late December.


Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer